J&J sues Samsung over a contract breach for a Stelara biosimilar

Taking stock of the drug industry, from the lab to the medicine chest

February 25, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

AP/Richard Drew STAT+ | J&J sues Samsung over a contract breach for a Stelara biosimilar Samsung Bioepis is one of several companies that settled patent litigation with J&J and won the right to sell biosimilar versions of Stelara. By Ed Silverman STAT+ | Eli Lilly to lower price of Zepbound vials, offer more doses The pharma giant is seeking to draw patients away from cheap, compounded copies of weight loss medications. By Elaine Chen STAT+ | Under siege after a tragedy, UnitedHealth grapples with fresh security threats and a customer backlash Thrust into the center of public anger, the conglomerate has become the poster child of a dysfunctional health care system By Tara Bannow, Bob Herman, Casey Ross, and Lizzy Lawrence

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser